1. Academic Validation
  2. N-acetyl-l-tryptophan, but not N-acetyl-d-tryptophan, rescues neuronal cell death in models of amyotrophic lateral sclerosis

N-acetyl-l-tryptophan, but not N-acetyl-d-tryptophan, rescues neuronal cell death in models of amyotrophic lateral sclerosis

  • J Neurochem. 2015 Sep;134(5):956-68. doi: 10.1111/jnc.13190.
Ana C Sirianni 1 Jiying Jiang 1 2 Jiang Zeng 3 Lilly L Mao 4 Shuanhu Zhou 5 Peter Sugarbaker 1 Xinmu Zhang 1 Wei Li 1 Robert M Friedlander 6 Xin Wang 1
Affiliations

Affiliations

  • 1 Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • 2 Department of Anatomy, Weifang Medical University, Weifang, Shandong, China.
  • 3 Institute of Analytical Chemistry for Life Science, School of Public Health, Nantong University, Nantong, Jiangsu, China.
  • 4 Aimcan Pharma Research & Technologies, Guelph, Canada.
  • 5 Department of Orthopedic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • 6 Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive motor neuron loss. Evidence suggests that mitochondrial dysfunction, Apoptosis, oxidative stress, inflammation, glutamate excitotoxicity, and proteasomal dysfunction are all responsible for ALS pathogenesis. N-acetyl-tryptophan has been identified as an inhibitor of mitochondrial cytochrome c release and therefore is a potential neuroprotective agent. By quantifying cell death, we demonstrate that N-acetyl-l-tryptophan (L-NAT) and N-acetyl-DL-tryptophan are neuroprotective in NSC-34 motor neuron-like cells and/or primary motor neurons, while their isomer N-acetyl-d-tryptophan has no protective effect. These findings are consistent with energy minimization and molecular modeling analysis, confirming that L-NAT generates the most stable complex with the neurokinin-1 receptor (NK-1R). L-NAT inhibits the secretion of Substance P and IL-1β (Enzyme-Linked Immunosorbent Assay and/or dot blots) and mitochondrial dysfunction by effectively inhibiting the release of cytochrome c/Smac/AIF from mitochondria into the cytoplasm and activation of apoptotic pathways, including the activation of Caspase-1, -9, and -3, as well as proteasomal dysfunction through restoring chymotrypsin-like, trypsin-like, and caspase-like Proteasome activity. These data provide insight into the molecular mechanisms by which L-NAT offers neuroprotection in models of ALS and suggest its potential as a novel therapeutic strategy for ALS. We demonstrate that L-NAT (N-acetyl-l-tryptophan), but not D-NAT, rescues NSC-34 cells and primary motor neurons from cell death. L-NAT inhibits the secretion of Substance P and IL-1β, and Caspase-1 activation, the release of cytochrome c/Smac/AIF, and the activation of Caspase -9, and -3, as well as proteasomal dysfunction. The data suggest the potential of L-NAT as a novel therapeutic strategy for amyotrophic lateral sclerosis (ALS). AIF, apoptosis-inducing factor.

Keywords

N-acetyl-l-tryptophan; amyotrophic lateral sclerosis; mitochondrial death pathway; neuroprotection; structure-bioactivity relationship; substance P.

Figures
Products